Transcriptomic risk scores for attention deficit/hyperactivity disorder

Judit Cabana-Domínguez1,2,3,4, Natalia Llonga5,6, Lorena Arribas5,6

  • 1Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. judit.cabana@vhir.org.

Molecular Psychiatry
|August 3, 2023
PubMed
Summary

This study reveals that transcriptomic risk scores (TRSs) derived from gene expression in blood are associated with Attention Deficit/Hyperactivity Disorder (ADHD). Combining TRSs with polygenic risk scores (PRS) enhances ADHD prediction, offering new insights into the disorder.